FIELD: medicine, phthisiology.
SUBSTANCE: method involves administration of vilon by parabulbar route in the dose 5 mg, every other day, by course for 10 procedures. Invention promotes to prevention of excessive scarring in the tuberculosis inflammation focus that, in turn, promotes to retention of visual function of eye based on penetration of vilon representing a peptide regulator through the blood-brain barrier being into eye posterior region tissues directly. Invention can be used in treatment of tuberculosis uveitis.
EFFECT: improved method of treatment.
2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING TUBERCULOUS UVEITES | 2006 |
|
RU2318534C2 |
| METHOD FOR TREATING SLOW CHRONIC TUBERCULAR UVEITIS | 2004 |
|
RU2283132C2 |
| METHOD OF TREATING CHORIORETINAL DYSTROPHIES AFTER TUBERCULOSIS CHORIORETINITIS | 2009 |
|
RU2463998C2 |
| REGENERATING RESOLVENT AND WAYS OF TREATMENT BY MEANS OF THIS AGENT | 2007 |
|
RU2362554C2 |
| METHOD FOR PREDICTING TUBERCULOUS UVEITIS THERAPY IN PATIENTS OF DIFFERENT AGE GROUPS | 2005 |
|
RU2294149C1 |
| AGENT INHIBITING ANGIOGENESIS IN VISUAL ORGAN DISEASE | 2001 |
|
RU2177801C1 |
| METHOD FOR TREATING DIABETIC RETINOPATHY | 1999 |
|
RU2157154C1 |
| METHOD FOR TREATING DYSTROPHIC DISEASES OF EYES | 2000 |
|
RU2195297C2 |
| METHOD OF REGISTERING APPEARANCE OF FOCAL RESPONSE IN CASE OF CHORIORETINITIS | 2011 |
|
RU2455935C1 |
| TETRAPEPTIDE STIMULATING EYE RETINA FUNCTION, PHARMACOLOGICAL AGENT BASED ON THEREOF AND METHOD OF ITS USING | 2000 |
|
RU2161982C1 |
